User-friendly, Safe Treatment Option for Kids with Epileptic Seizures Discovered

Epileptic seizures in children are treated using phenytoin, a second-line intravenous anticonvulsant. However, levetiracetam could be an effective and safer alternative for the treatment of pediatric convulsive status epilepticus, reveals a new study. The findings of the study are published in the journal The Lancet.

Every day in the UK, 87 people are diagnosed with epilepsy, affecting over 600,000 people. Many people with a new diagnosis of epilepsy will experience memory and other cognitive problems. The cause of these problems is unknown.

Epilepsy During Pregnancy - Causes, Symptoms, Complications, Treatment
Seizures or epilepsy during pregnancy can be fatal for both the mother and child and needs urgent medical intervention. The reasons are often unknown.

‘Levetiracetam could be considered as a safe alternative treatment to phenytoin for second-line management of pediatric convulsive status epilepticus.’
Read More..

Tweet it Now

It has an annual incidence of 20 per 100?000 children and is the second most common reason for unplanned admissions to pediatric intensive care units (PICUs) in the UK.

Anti-epileptic drugs (AEDs), also known as anticonvulsants, are used to control seizures in people with epilepsy.

Convulsive status epilepticus (CSE) is the situation when a tonic-clonic seizure doesn't stop either on its own or with anticonvulsants. It is the most common life-threatening neurological emergency in children.

Fits | Epilepsy | Convulsions - Causes Symptoms Diagnosis Treatment FAQs
Fits or convulsions or Epilepsy is characterized by recurrent, involuntary seizures and is described as a chronic neurological disorder

Currently, CSE is treated using an algorithm which incorporates 10 min intervals between treatments. Second-line treatment is given when CSE persists either after two doses of the first-line treatment, which is an anticonvulsant called a benzodiazepine, or the child's personalized emergency (rescue) treatment.

The anticonvulsant medication phenytoin has been used as the usual second-line treatment of CSE for several decades and is known to have rare but potentially dangerous side effects. However, some evidence suggests that another medication, levetiracetam could be an effective and safer alternative. To ascertain which treatment was safest and most effective the EcLiPSE Team, made up of doctors from Alder Hey and Bristol Children's Hospitals together with research teams from the Universities of Liverpool and the West of England, conducted a trial to compare the efficacy and safety of both drugs for second-line management of CSE.

Juvenile Myoclonic Epilepsy - Causes Symptoms Diagnosis Treatment & Prevention
Juvenile myoclonic epilepsy is a form of generalized seizure characterized by sudden jerky movements of both arms and shoulders, usually just after waking up.

The EcLiPSE Team is led by Professor Richard Appleton, a Merseyside pediatric neurologist based at the University of Liverpool's Department of Women's and Children's Health, and Alder Hey Children's Hospital Trust.

Between 2014 and 2018 the team conducted a randomized clinical trial involving 30 UK Emergency Departments and almost 300 children.

Sleep Disorders Associated with Epilepsy
Epilepsy and sleep disorders have a profound effect on each other. Epileptic seizures can disturb sleep; sleep disorders like sleep apnea, RLS can aggravate seizures.

The results did not show that levetiracetam was better than phenytoin, in stopping CSE. However, overall the results suggest levetiracetam may be considered as an alternative treatment to phenytoin.

Professor Richard Appleton, said: "The EcLiPSE trial has given doctors new and unique evidence for the choice of anticonvulsant and how to best treat this childhood neurological emergency.

"Our results suggest that levetiracetam could be considered as an alternative treatment to phenytoin for second-line management of pediatric CSE. Possible benefits of levetiracetam over phenytoin include its ease of preparation and administration, minimal interaction with antiepilepsy and other drugs, and easy conversion to oral maintenance therapy. Further randomized clinical trial and meta-analysis data could help to confirm our results and might lead to levetiracetam being the preferred second-line anticonvulsant in children with benzodiazepine-resistant convulsive status epilepticus.

"The trial also highlights the importance of close and effective collaboration between two specialties in pediatrics, neurology and emergency medicine that will improve the care of children with epilepsy."

Source-Eurekalert